Rigel Pharmaceuticals Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class as disclosed. The amendment explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately.
Rigel Pharmaceuticals reported very strong fourth quarter and full-year 2025 results driven by its hematology and oncology portfolio. Fourth quarter 2025 total revenues were $69.8 million, with net product sales of $65.4 million, up 41% from 2024, and contract revenues of $4.4 million. Net income for the quarter surged to $268.1 million, or $13.54 diluted per share, largely reflecting a $245.9 million non-cash deferred income tax benefit.
For 2025, total revenues were $294.3 million, including $232.0 million of net product sales, which grew 60% year over year, and $62.3 million of contract revenues. Full-year net income was $367.0 million, or $19.48 diluted per share. Cash, cash equivalents and short-term investments increased to $155.0 million as of December 31, 2025, from $77.3 million a year earlier.
Rigel continues to advance its pipeline, particularly the Phase 1b study of R289 in lower-risk myelodysplastic syndrome, with dose expansion enrollment ongoing and recommended Phase 2 dose selection expected in the second half of 2026. For 2026, the company anticipates total revenues of $275 to $290 million and positive net income while funding existing and new clinical programs.
Rigel Pharmaceuticals outlines a growing hematology and oncology business built around three FDA‑approved drugs and a developing pipeline. In 2025, TAVALISSE net sales reached $158.8 million, up 51.6% from 2024, while REZLIDHIA sales grew to $31.0 million and GAVRETO to $42.1 million.
The company is advancing R289 for lower‑risk myelodysplastic syndromes, with Phase 1b data showing durable transfusion independence in some heavily pretreated patients and Orphan Drug and Fast Track designations. Rigel also expands olutasidenib into new indications through collaborations with MD Anderson and CONNECT, while a settlement on TAVALISSE patents allows a generic entrant no earlier than the second quarter of 2032.
Rigel Pharmaceuticals director Walter H. Moos reported option and share transactions. On February 20, 2026, he exercised a stock option for 4,000 shares of common stock at $24.00 per share through a derivative exercise or conversion.
On the same date, he sold 4,000 shares of common stock in an open-market or private transaction at $36.36 per share. After these transactions, he directly owned 12,722 shares of Rigel Pharmaceuticals common stock. The reported numbers reflect a prior one-for-ten reverse stock split.
Rigel Pharmaceuticals executive Raymond J. Furey reported an equity compensation award in the form of Restricted Stock Units tied to the company’s common stock. The award covers 19,497 shares, reflected as an acquisition with no cash price because it is a grant, not an open-market purchase.
These Restricted Stock Units will vest quarterly over a three-year period, with the first quarterly vesting scheduled for March 31, 2026. Following this award, Furey is shown as having 51,813 shares of common stock in direct ownership, illustrating his ongoing equity alignment with the company.
Rojkjaer Lisa reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Lisa Rojkjaer received a grant of 18,894 shares of common stock in the form of Restricted Stock Units. These RSUs will vest quarterly over three years, starting with the first vesting on March 31, 2026. After this award, she is reported to beneficially own 34,853 shares of common stock directly.
Rigel Pharmaceuticals CEO and President Raul R. Rodriguez reported an equity award on common stock. He acquired a grant of 53,915 shares through a Restricted Stock Unit award at a stated price of $0.00 per share. According to the award terms, these Restricted Stock Units will vest quarterly over three years, with the first vesting date on March 31, 2026. After this grant, Rodriguez directly owns 282,017 shares of common stock.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported an equity award of company stock. He acquired 20,636 shares of common stock through a grant of restricted stock units at a stated price of $0.00 per share. Following this grant, he directly holds 76,337 common shares.
The award vests over time rather than all at once. The restricted stock units are scheduled to vest quarterly over three years, with the first quarterly vesting date on March 31, 2026. As each portion vests, the corresponding shares of common stock will be delivered to him.
Santos David A reported acquisition or exercise transactions in this Form 4 filing.
Rigel Pharmaceuticals executive David A. Santos reported an equity grant. He was awarded 19,430 shares of common stock at a price of $0.00 per share, tied to a Restricted Stock Unit award. The RSUs will vest quarterly over three years, starting on March 31, 2026, increasing his direct ownership to 62,870 shares as they vest.